MelliCell develops therapeutics for chronic disease using proprietary technologies that model weight gain in human fat cells in vitro. Our core technology enables discovery of novel therapeutic targets and drugs that can overcome the limitations of existing therapies and correct fat cell dysfunction that causes chronic disease. Our technology efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes and disease hallmarks of fat cells in patients. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts chronic disease better than obesity per se. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Newton, Ma 02458, Us
- Industry
- Biotechnology
- Website
- mellicell.com
- HQ
- Newton, MA
Mellicell, Inc. Questions
Mellicell, Inc.'s website is mellicell.com
Mellicell, Inc.'s LinkedIn profile is https://www.linkedin.com/company/mellicell
Mellicell, Inc. has
10 employees.
View email and phone details for 10
employees at Mellicell, Inc..
Mellicell, Inc.'s industry is
Biotechnology
Mellicell, Inc.'s top competitors are
Extend Biosciences, Inc.,
Plutosec,
Planet 3r,
Autobuddy Inc,
Kenvue,
Savran Technologies Inc.,
Intelycare,
Enveda,
Partna (Yc W22),
Ventogram.
Mellicell, Inc.'s categories are Biotechnology
Mellicell, Inc.'s founding year is 2020
